FDA advisors back Moderna's mRNA flu vaccine

An independent advisory panel for the FDA has unanimously recommended approval for Moderna's mRNA-based seasonal flu vaccine, mFlusiva. This decision follows a period of controversy where a Trump administration appointee initially blocked the vaccine's review. Data from large-scale trials indicated the vaccine is more effective than standard flu shots and shows a robust immune response in older adults, with a generally good safety profile. The mRNA platform offers rapid development capabilities, crucial for adapting to new flu strains and potential future pandemics.